Introduction
============

Nasopharyngeal cancer (NPC), a unique malignancy of the head and neck, is endemic to southeast Asia, northern Africa, and middle Europe where the acute incidence is 15-50 cases per 100,000 annually [@B1]. The latest GLOBOCAN data [@B2] in 2018 reported that 129,097 patients were newly diagnosed with NPC worldwide. Of these patients, 47.7% were in China.

Due to the high sensitivity to radiation and the complicated anatomical structure of the nasopharynx, radiation therapy (RT) is regarded as the mainstay of treatment for NPC. Previously, conventional two-dimensional RT was a common technique for NPC. In early reports, the 5-year survival rate of NPC after two-dimensional RT was 67-76% [@B3]-[@B7]. However, late complications, including carotid stenosis, optic neuropathy, and brain necrosis, reduced the quality of life in long-term survivors [@B8]-[@B10].

Compared with two-dimensional RT, intensity-modulated radiation therapy (IMRT) could improve the dose covering the clinical target volume (CTV) in three dimensions while protecting the normal tissues around the CTV [@B11]. \]. Moreover, IMRT provides favorable local control and survival outcomes in NPC [@B12]-[@B18]. In contrast to non-IMRT techniques, IMRT improves cancer-specific survival for head and neck cancer according to the Surveillance, Epidemiology, and End Results (SEER) databases, especially in NPC patients [@B19]. IMRT can be implemented using a sequential (SEQ) or simultaneous integrated boost (SIB) protocol. SEQ IMRT uses a two-phase shrinkage technique, while SIB IMRT delivers different dose levels to different target volumes. Compared with SEQ IMRT, SIB IMRT yields more satisfactory dosimetric outcomes for nearby critical organs and is regarded as the standard therapy for NPC [@B20]-[@B22]. In addition, whole-field SIB IMRT provides more dosimetric benefits for the larynx and fewer set-up errors than junction IMRT with a conventional RT field [@B23].

Currently, due to the introduction of Magnetic Resonance (MR) and induction chemotherapy (IC), IMRT has significantly improved the survival rate of NPC to 80-85% [@B12]-[@B14]. A recent study reported that the locoregional relapse-free survival (LRRFS), distant metastasis-free survival (DMFS), and disease-specific survival (DSS) of 865 NPC patients in 2001-2008 were 92%, 83.4%, and 78.6%, respectively, 10 years after IMRT [@B24]. However, insufficient RT dose is still one of the most important factors affecting the therapeutic effect. In many previous protocols [@B12]-[@B14], [@B16]-[@B18], bone mark and wide margins from the GTV of the nasopharynx and cervical lymph nodes were used to encompass the high-dose area. These experiences came from conventional two-dimensional RT techniques. Although IMRT provides encouraging local control and survival outcomes, normal tissues are also exposed to unnecessarily high doses, and some late complications such as hearing loss, carotid stenosis, optic neuropathy, and brain necrosis occur in long-term survivors [@B8]-[@B10], [@B25]. Ng and colleagues [@B26] evaluated the effect of dosimetric inadequacy in target volumes on the local control of NPC; the results indicated that if the volume in the gross tumor volume (GTV) below 66.5 Gy was more than 3 cc, the 5-year rate of local failure-free survival dropped to 54%. Both target volumes and prescribed doses are vital for IMRT in NPC. Recently, a global questionnaire study proposed a CTV design scheme for NPC, i.e., the principle of "5 + 5 mm expansion." Based on the GTV, the high-risk CTV is formed by expanding 5 mm, and then the low-risk CTV is formed by a further expansion of 5 mm [@B27]. However, there are no available data regarding the expansion of NPC tumors and no radical dose for the GTV. If the CTV is obtained by uniform expansion from the GTV, excessive normal tissue may be irradiated. Therefore, reduced target volumes have been used to apply IMRT in NPC [@B15]-[@B17]. However, optimal target volumes and doses of IMRT in NPC remain unclear due to a lack of available data on the extent of the invasion of the NPC tumor.

Considering the above situation, we designed a protocol for different risk target volumes and corresponding prescribed doses in SIB IMRT based on the characteristics of the gradual spread of the tumor. The main objectives were to introduce our protocol and investigate the long-term results and adverse events in patients with NPC treated with our protocol.

Materials and Methods
=====================

Patients
--------

Between January 2013 and December 2014, 355 patients hospitalized at the Department of Radiation Oncology at Zhejiang Cancer Hospital were retrospectively reviewed. Eligible patients met the following criteria: (i) biopsy-proven NPC, (ii) no metastasis occurred, (iii) received SIB IMRT using our protocol, (iv) completion of treatment, and (v) no previous anti-cancer treatment. Patients who did not complete definitive IMRT, those without metastasis at diagnosis, or those who had received previous anti-cancer treatment were excluded. This retrospective study was approved by the Medical Ethics Committee and the Institutional Review Board of Zhejiang Cancer Hospital. All treatment protocols in this study were carried out in accordance with the National Comprehensive Cancer Network guidelines. Due to the retrospective design of the study, the committee confirmed that informed consent was not required.

Pretreatment evaluations
------------------------

Pretreatment evaluations included the following: detailed medical histories, evaluation of performance status, and careful physical examinations. Magnetic resonance imaging (MRI) of the nasopharynx and nasopharyngoscopies was performed. Chest computed tomography (CT), bone scans, abdominal ultrasound, and hematology and biochemistry tests were conducted 1 week before treatment. Positron emission tomography scans and abdominal CT scans were performed as clinically indicated. The 2010 American Joint Committee on Cancer staging system and World Health Organization classification were recommended for use in this study.

SIB IMRT
========

Body position fixation and scanning requirements
------------------------------------------------

All patients receiving SIB IMRT were immobilized in the supine position using thermoplastic masks. CT scans with intravenous contrast using 2.5-mm slices from the head to a level 2 cm below the sternoclavicular joints were performed for planning. Intravenous contrast was administered at approximately 1-2 mL/kg/s.

Names and relationship of different risk target volumes
-------------------------------------------------------

Based on the orderly stepwise pattern of tumor spread, we designed three or four risk target volumes in the pathway of NPC tumor invasion including the peripheral (Figure [1](#F1){ref-type="fig"}A), upper, and lower structures (Figure [1](#F1){ref-type="fig"}B). The corresponding target volumes included high-risk planning target volume of nasopharyneal GTV (PGTVnx) or planning target volume of GTV in cervical lymph nodes (PGTVnd) encompassing GTV of nasopharynx (GTVnx) or GTV of cervical lymph nodes (GTVnd), intermediate-risk planning target volume of nasopharyx (PTVnx) or planning target volume of neck area (PTVna) encompassing CTV of nasopharynx (CTVnx) or CTV of neck area (CTVna), and low-risk planning target volume (PTV) encompassing CTV. If the retropharyngeal lymph nodes (RLNs) were large or resistance to IC, we add a higher risk target volume for PTV of GTV in retropharyngeal lymph nodes (PGTVrpn) encompassing GTV of retropharyngeal lymph nodes (GTVrpn). The relationship of the three to four risk tumor volumes such as PGTVnx (PGTVrpn), PGTVnd, PTVnx, PTVna, and PTV is shown in Figure [1](#F1){ref-type="fig"}.

Definitions of the different risk target volumes
------------------------------------------------

According to the orderly stepwise pattern of tumor spread, we designed the different risk target volumes as follows. GTV referred to the macroscopic tumor extent found in clinical and imaging baseline examinations or before treatment. The primary tumor extent including the metastatic retropharyngeal lymph nodes (RLNs) was named the GTVnx, and the metastatic lymph nodes of the neck were named the GTVnd. If the RLNs were large and resistant to IC, we add a GTVrpn into the GTVnx. Based on the above for each GTV, we automatically expanded the margin by an additional 1-3 mm in three dimensions to get the corresponding PTVs, including PGTVnx, PGTVnd, and PGTVrpn.

The CTV included the high-risk CTV (CTVnx and CTVna) and low-risk CTV according to the orderly stepwise pattern of tumor spread and the risk region potentially involved around the nasopharyngeal cavity. For stage T1-2, CTVnx was defined as GTVnx plus a 5-7-mm margin encompassing the entire nasopharyngeal mucosa plus 5 mm of the submucosal volume. For stage T3-4, CTVnx was defined as GTVnx plus a 5-7-mm margin encompassing the entire nasopharyngeal mucosa plus 5 mm of the submucosal volume, parapharyngeal space, pterygoid fossae, and foramen lacerum. PTVnx was created automatically by adding a 1-3-mm margin in three dimensions. For stage N0, CTVna was defined as lymphatic drainage clearance in level II of the bilateral neck, while for stage N1-3, CTVna included GTVnd plus a 2-5-mm margin, the ipsilateral lymph drainage space 2 cm below the GTVnd, and the contralateral lymphatic drainage clearance in level II. PTVna was created automatically by adding a 1-3-mm margin. The low-risk CTV included the CTVnx plus a 5-10 mm margin, CTVnx plus a 2-5-mm margin, and the prophylactic low-risk neck irradiation area. The low-risk PTV was defined as the low-risk CTV plus a 3-mm margin.

All of the PTVs, including PGTVnx, PGTVnd, PTVnx, PTVna, and PTV, were trimmed so as not to be delineated outside of the skin surface. Table [1](#T1){ref-type="table"} and Figures [2](#F2){ref-type="fig"}-[4](#F4){ref-type="fig"} demonstrate the delineations of different risk target volumes using our protocol.

General principles of different risk target volume design
---------------------------------------------------------

In one CT image slice, if there is a GTV, the peripheral structures of the NPC tumor (primary tumor and cervical lymph nodes) invasion should be divided into three tumor volumes of high-, medium-, and low risk such as the PGTVnx/nd, PTVnx/na, and PTV. Moreover, three prescribed dose levels are given for the corresponding risk target volumes.

In one CT image slice, if there is a high-risk area but no GTV, two risk target areas and two prescription dose levels for medium- and low risk should be designed.

In one CT image slice, if there is neither a GTV nor a high-risk area but it includes a low-risk area, a target area and a prescription dose for low risk should be designed.

Dose prescription
-----------------

Doses of 70.5, 70.5, 63, 60, and 51 Gy in 30 fractions were administered to the PGTVnx, PGTVnd, PTVnx, PTVna, and PTV, respectively. If PGTVrpn was added into PGTVnx, a dose of 73.5 Gy in 30 fractions was delivered. SIB IMRT was performed once daily, in five fractions per week, over 6 weeks according to the IMRT planning.

Delineation of organs at risk
-----------------------------

Critical normal structures, including the brainstem, spinal cord, parotid glands, optic nerves, chiasm, lens, eyeballs, temporal lobes, temporomandibular joints, mandible, and hypophysis, were contoured and set as organs at risk (OARs) during optimization.

Chemotherapy
------------

Out of 335 patients, 302 received three-weekly platinum-based IC, 313 underwent three-weekly concurrent chemotherapy with cisplatin, and 199 received adjuvant chemotherapy (AC). The available IC regimens included TPF (docetaxel 60 mg/m^2^/day on day 1, cisplatin 25 mg/m^2^/day on days 1-3, and 5-fluorouracil 500 mg/m^2^/day on days 1-3), TP (docetaxel 60 mg/m^2^/day on day 1, cisplatin 25 mg/m^2^/day on days 1-3), GP (gemcitabine 1,000 mg/m^2^/day on days 1 and 8, cisplatin 25 mg/m^2^/day on days 1-3), and FP (cisplatin 25 mg/m^2^/day on days 1-3, 5-fluorouracil 500 mg/m^2^/day on days 1-3). The one to two cycles of AC consisted of cisplatin and 5-fluorouracil.

Plan evaluation
---------------

Plans were compared by target coverage according to the cross-section dose distribution and the dose-volume histogram (DVH) of the targets. Parameters of the DVH were evaluated as follows: 1) doses received by 95% and 90% of the volumes of the PTV (D95 and D90, respectively), maximum PTV dose (Dmax), minimum PTV dose (Dmin), and mean PTV dose; 2) maximum OARs dose and the volume of OARs receiving a high dose; and 3) the volume received 30 or 40 Gy of the normal tissues.

Adverse events and survival evaluation
--------------------------------------

Adverse events were assessed according to the common toxicity criteria of the National Cancer Institute. Survival was calculated from the date of diagnosis to the date of the most recent follow-up, recurrence, or death. The pattern of failure was defined according to the first site of failure: recurrence of the primary tumor or metastasis to regional lymph nodes was regarded as locoregional failure, and metastasis to any site beyond the primary tumor and regional lymph nodes was defined as distant failure.

Endpoints and statistical analysis
----------------------------------

The endpoints of the present study were LRRFS (time from the date of confirmed NPC to locoregional failure), DMFS (time from the date of confirmed NPC to distant metastasis), progression-free survival (PFS) (time from the date of confirmed NPC to progression), OS (time from the date of confirmed NPC to the last follow-up), and acute adverse events from IC and IMRT. If patients relapsed or developed metastasis, they underwent salvage therapy as determined by their physicians. The Kaplan-Meier method was used to generate LRRFS, DMFS, PFS, and OS curves. All data were analyzed using SPSS Statistics version 22.0 (IBM Corp, Armonk, NY).

Results
=======

Patient characteristics
-----------------------

From May 2008 to April 2014, the clinical data of 332 untreated, newly diagnosed NPC patients who were initially treated with additional IC followed by SIB IMRT in the Department of Radiation Oncology, Zhejiang Cancer Hospital (Hangzhou, People\'s Republic of China) were collected and retrospectively reviewed. The basic characteristics of the patients are summarized in Table [2](#T2){ref-type="table"}. All patients completed a full course of radical IMRT and received one to four cycles of IC.

Delineation of different risk target volumes and IMRT planning
--------------------------------------------------------------

To illustrate our protocol of different risk target volumes, a histology-proven NPC patient was used to describe the different risk target volumes and the corresponding doses in IMRT planning. The MRI of this patient indicated that the primary tumor had invaded the parapharyngeal space, bilateral metastatic RLNs had occurred, and multiple metastatic lymph nodes were observed in the bilateral cervical and supraclavicular regions (Figure [5](#F5){ref-type="fig"}A). Therefore, the stage was T2N3M0. The patient received three cycles of TP-based IC. After CT simulation following the third IC, we delineated three risk target volumes including high-risk PGTVnx and GTVnd, intermediate-risk PTVnx and PTVna, and low-risk PTV. The IMRT planning was designed by an experienced physicist. Dose distribution was even (Figure [5](#F5){ref-type="fig"}B). The DVH showed that the prescribed doses met our requirements (Figure [5](#F5){ref-type="fig"}C).

Patterns of failure
-------------------

Among all patients, 47 experienced treatment failure. Twenty-one had locoregional recurrence within the high-dose GTV. Twelve patients developed regional relapse only, and 10 received salvage surgery; eight patients experienced local recurrence only, and one had both local and regional relapse. Twenty-two patients experienced ≥1 distant metastasis, 21 of whom died from disease progression. Four patients experienced locoregional relapse and distant metastasis. Regarding the metastatic location, six patients developed pulmonary metastasis only, eight experienced bone metastases, two developed hepatic metastasis and six developed multiple organ metastases.

Long-term survival
------------------

A total of 407 patients were treated with SIB IMRT. Among them, 36 were excluded from further analysis due to loss to follow-up; thus, 335 participants remained. During the follow-up duration of 70 months, the rates of 3-, 5-, and 7-year LRRFS were 94.1%, 92.3%, and 91.3%, respectively (Figure [7](#F7){ref-type="fig"}A). The distant metastases-free survival rates at 3-, 5-, and 7-year were 92.7%, 92.1%, and 92.1%, respectively (Figure [7](#F7){ref-type="fig"}B). The 3-, 5-, and 7-year progression-free survival rates were 88.2%, 85.9%, and 85.0%, respectively (Figure [7](#F7){ref-type="fig"}C). The rates of OS at 3-, 5-, and 7-year were 90.1%, 86.3%, 82.3%, respectively (Figure [7](#F7){ref-type="fig"}D). Furthermore, there were no significant differences in LRRFS between T-stage (Figure [8](#F8){ref-type="fig"}A) and N-stage (Figure [8](#F8){ref-type="fig"}B) NPC patients.

Adverse events
--------------

For patients treated with IC or AC, adverse events were recorded as IC- or AC-related acute toxicities, while for patients who received RT with or without concurrent chemotherapy (CC), adverse events were recorded as RT-related acute toxicities. If adverse events occurred after a follow-up duration of 6 months, they were recorded as late toxicities. No patient in this study died from treatment-related adverse events.

Table [3](#T3){ref-type="table"} lists the profiles of IC- and RT-related complications. During the period of IC, 94 (28.1%) and 109 (32.5%) patients experienced grade 3-4 leukopenia and neutropenia, 12 and 13 patients developed grade 3-4 anemia and thrombocytopenia, while the rates of grade 3-4 mucositis, diarrhea, and nausea were 2.1%, 2.1%, and 7.5%, respectively. During the period of IMRT, the incidences of grade 3-4 leukopenia, neutropenia, anemia, and thrombocytopenia were 10.4%, 10.1%, 1.5%, and 2.1%, respectively. Moreover, 23 and 11 patients experienced grade 3 mucositis and dermatitis, respectively.

Complications such as dry mouth, hearing loss, carotid stenosis, cranial nerve paralysis, and brain necrosis were regarded as common late adverse events. Of these late adverse events, xerostomia was the most common late complication, and most survivors at the last follow-up experienced mild-to-moderate xerostomia. No grade 2 or higher xerostomia occurred in survivors. However, grade 3 unilateral or bilateral hearing loss was reported in 43 patients (12.8%). Five patients developed cranial nerve damage in the posterior group. Carotid stenosis was observed in two patients. Based on MRI, radiation encephalopathy occurred in 16 patients, two of which developed temporal lobe necrosis.

Biological effective dose
-------------------------

In our protocol, the high-risk PGTVnx and PGTVnd received doses of 70.5-72 Gy and 69-70.5 Gy, respectively; the intermediate-risk PTVnx and PTVna received doses of 63-66 Gy and 60-63 Gy, respectively; and the low-risk PTV received 51-54 Gy. All doses were administrated in 30 fractions. The biological effective doses (BEDs) of our protocol were calculated using the linear-quadratic model according to the early (α/β = 10) and late (α/β = 3) tissue response parameters. The BEDs of our protocol were similar to the IMRT dose regimens in the China protocol [@B28] and 0615 protocol [@B29] (Table [4](#T4){ref-type="table"}). Furthermore, after the equivalent formula conversion, the corresponding equivalent doses in 2 Gy/fraction (EQDs2) of our protocol were 73.44, 63.53, 60, and 49.73 Gy in 70.5Gy/30F, 63Gy/30F, 60Gy/30F and 51Gy/30F, respectively.

Plan comparison
---------------

To evaluate the dosimetric benefits of our protocol, we selected two patients with T4-stage NPC. Target volumes for one patient were delineated using the China protocol, and our protocol was used for the other patient. In the China protocol, doses of 70.4, 70.4, 64, 60.8, and 54.4 Gy in 32 fractions were administered to PGTVnx+rn, PGTVnd1, PGTVns2, PTV1, and PTV2, respectively, while doses of 70.5, 70.5, 63, 60, and 51 Gy in 30 fractions were administered to PGTVnx, PGTVnd, PTVnx, PTVna, and PTV. The two IMRT plans met the requirements. Compared with the China protocol, our strategy led to reductions in the V40 and V30 (Figure [5](#F5){ref-type="fig"}A and [5](#F5){ref-type="fig"}B) and D2 and D1 (Figure [6](#F6){ref-type="fig"}C and Figure [6](#F6){ref-type="fig"}D). For the three risk target volumes, the high dose was more concentrated in the GTV, and the area receiving a low dose was decreased.

Discussion
==========

According to the 2019 National Comprehensive Cancer Network guidelines, RT plus concurrent chemotherapy with IC or AC is the preferred treatment for NPC. IMRT has shown remarkable promise in the treatment of NPC. However, optimal target volumes and prescribed doses in IMRT for NPC were unclear. A better understanding of the pathway of NPC tumor spread was used to delineate target tumors and increase survival. Here, we described our protocol of different risk target volumes based on the orderly stepwise pattern of tumor spread. Moreover, we report the long-term survival and adverse events of our protocol. The BEDs of the prescribed doses in our protocol were similar to those of the China and 0615 protocols. Further, our protocol resulted in decreases in D1 and D2 in the GTV, while V30 and V40 in normal tissues were lower. In addition, our protocol offered acceptable adverse events and favorable long-term survival outcomes with 5-year LRRFS of 92.2%, 5-year DMFS of 92.1%, 5-year PFS of 85.9%, and 5-year OS of 86.3%. Most importantly, no recurrence occurred in the margins or outside of the high-dose area for all survivors with our protocol.

Because of its highly infiltrative nature, NPC tumors easily invade areas of loose tissue and spread along the lacunae and neural foramen. The extent of invasion and the route of spreading have been described based on MRI findings [@B30]. According to the risk ratios of the invaded anatomic structures around the nasopharynx, Liang et al. [@B31] and Li et al. [@B32] divided these anatomic sites into high- (≥50%), medium- (5-30%), and low-risk (\<5%) regions. Based on the above results, many Chinese experts with extensive experience in the treatment of NPC proposed a protocol in 2010 [@B28]. This protocol is used by most hospitals in China, and favorable survival outcomes have been demonstrated for this protocol. However, it remains unclear whether all the high-risk areas are invaded in each NPC patient. If we include all the high-risk regions and the extension expands uniformly from the GTV, normal tissues are exposed to excessively high doses of radiation. To decrease the doses to normal tissues, reduced target volumes were applied for NPC [@B15]-[@B17], [@B33]. Lin and colleagues [@B15], [@B16] used reduced target volumes in IMRT for NPC, and their protocol provided promising local control and survival with acceptable adverse events. Sanford and colleagues [@B17] designed individual delineations of the CTV for 73 NPC patients treated with IMRT; they found that the 5-year local control, regional control, and OS rates were 94%, 99%, and 84%, respectively. The reduced-volume protocol designed by Billan et al. [@B33] decreased the volumes of PTV of primary tumor (PTV-P) by 27.6% compared to those in RTOG 0615, and the 3-year disease-free survival was 75%. Given the present situation, international guidelines introduced the principle of the "5 + 5 mm expansion" margin from the GTV (Table [4](#T4){ref-type="table"}) [@B27]. This protocol was based on consensus from international experts with experience in the treatment of NPC. The theoretical basis was derived from the data on the microscopic extension from recurrent NPC tumors [@B34] and other head-neck cancers [@B35],[@B36]. Unfortunately, no clinical survival outcomes using this protocol were reported.

In addition, a better understanding of prescribed doses is needed. In the era of conventional RT, the isocenter dose was often 66-70 Gy in 30 fractions. Chau et al. [@B37],[@B38] used a three-dimensional treatment planning system to evaluate the actual dosimetric distribution of Ho\'s technique for NPC; the results showed that the D95s of the GTV and PTV in an isocenter dose of 66 Gy are about 57 Gy and 45 Gy, respectively. Kam et al. [@B39] indicated that Ho\'s technique offers a D95 of 62.5 Gy in the GTV and 52.5 Gy in the PTV for T1 NPC patients, a D95 of 63 Gy in GTV and 57.5 Gy in PTV for T2 patients, and a D95 of 65 Gy in GTV and 55 Gy in PTV for T4 cases. Our previous study demonstrated that conventional RT techniques provide 63.8 Gy for D95 in PGTVnx, 63 Gy for D95 in PTVnx, and 42.5 Gy for D95 in PTV [@B40]. Although the dose distributions of conventional RT techniques were unsatisfactory, the local control rate was about 80%. Based on these results, the prescribed doses of IMRT were 66-70 Gy to the GTV. However, an insufficient dose to the GTV in T3-4 NPC patients treated with IMRT was related to poor local control [@B41]. Thus, data of appropriate prescribed doses for target volumes are lacking.

Accordingly, we divided the tumor and the anatomic sites around the tumor into three or four risk target volumes based on the orderly stepwise pattern of tumor spread (Table [1](#T1){ref-type="table"}). High-risk PGTVnx and PGTVnd were irradiated with high doses, intermediate-risk PTVnx and PTVna were irradiated with intermediate doses, and low-risk PTV was irradiated with low doses. If the RLNs were large or resistance to IC, we add PGTVrpn to PGTVnx and administered a higher dose. Using our protocol, the high dose was more concentrated in the GTV, and the areas receiving a low dose were decreased. The BEDs of our protocol were similar to those of the IMRT dose regimens in the China and 0615 protocols (Table [4](#T4){ref-type="table"}). Moreover, the corresponding EQDs2 of our protocol were 73.44, 63.53, 60, and 49.73 Gy in 70.5Gy/30F, 63Gy/30F, 60Gy/30F and 51Gy/30F, respectively. Notably, the LRRFS, DMFS, PFS, and OS rates at 5 years were 92.2%, 92.1%, 85.9%, and 86.3%, respectively.

Although the present protocol provided favorable dosimetric parameters and survival outcomes with fewer acute and late adverse events, several limitations of our study should be noted. First, as this was a single-center study, all the limitations associated with single centers apply. Second, due to the retrospective nature of the study, it provided relatively low power to indicate the superiority of our protocol. Third, acute adverse events were assessed according to medical records; no quality-of-life assessments were performed for long-term survivors. Moreover, the effect of IC has not been considered in our protocol. Thus, our protocol should be regarded as preliminary. Our revised protocol should be verified in future prospective and large-sample clinical trials.

Conclusion
==========

We presented a protocol of different risk target volumes and corresponding prescribed doses for IMRT in NPC patients. Our protocol resulted in superior dose distributions for reducing high-dose volumes in the GTV and decreasing low-dose volumes in normal tissues. The present regimen provided favorable long-term survival outcomes with acceptable acute and late adverse events. Therefore, this protocol can be recommended for the treatment of NPC.

Funding
-------

This study was supported by grants from the Medical and Health Science and Technology Program of Zhejiang Province (No. 2020KY084, No. 2019KY041, No. 2013KYB033, No. 2009B026, No. 2006A016, No. 2005B012, and No. 2004B014) and the National Natural Science Foundation of China (No. 81502647).

AC

:   adjuvant chemotherapy

BED

:   biological effective dose

CT

:   computed tomography

CTV

:   clinical target volume

CTVna

:   CTV of neck area

CTVnx

:   CTV of nasopharynx

DMFS

:   distant metastasis-free survival

DVH

:   dose-volume histogram

EQDs2

:   equivalent doses in 2 Gy/fraction

GTV

:   gross tumor volume

GTVnd

:   GTV of cervical lymph nodes

GTVnx

:   GTV of nasopharynx

GTVrpn

:   GTV of retropharyngeal lymph nodes

IC

:   induction chemotherapy

IMRT

:   intensity-modulated radiotherapy

LRRFS

:   locoregional relapse-free survival

MRI

:   magnetic resonance imaging

NPC

:   nasopharyngeal cancer

OAR

:   organ at risk

OS

:   overall survival

PFS

:   progression-free survival

PGTVnd

:   planning target volume of GTV in cervical lymph nodes

PGTVnx

:   planning target volume of GTV in nasopharynx

PGTVrpn

:   planning target volume of GTV in retropharyngeal lymph nodes

PTV

:   planning target volume

PTVna

:   PTV of neck area

PTVnx

:   PTV of nasopharynx

RLN

:   retropharyngeal lymph node

RT

:   radiotherapy

SEER

:   Surveillance, Epidemiology, and End Results

SEQ

:   sequential

SIB

:   simultaneously integrated boost

V30

:   the volume received 30

V40

:   the volume received 40 Gy

![**The different risk target volumes.** (**A**) Cross section; (**B**) coronary position. Red: PGTVrpn; orange: PGTVnx; yellow: PGTVnd; green: PTVnx; pink: PTVna; blue: PTV. Abbreviations: PGTVrpn: planning target volume of GTV in retropharyngeal lymph nodes; PGTVnx: planning target volume of nasopharyngeal GTV; PGTVnd: planning target volume of GTV in cervical lymph nodes; PTVnx: planning target volume of nasopharynx; PTVna:planning target volune of neck area; PTV: planning target volume.](jcav11p5210g001){#F1}

![Selected computed tomography slices to demonstrate the delineation of different risk target volumes. Red: PGTVnx; yellow: PGTVnd; green: PTVnx; pink: PTVna; blue: PTV1. Abbreviations: PGTVnx: planning target volume of nasopharyngeal GTV; PGTVnd: planning target volume of GTV in cervical lymph nodes; PTVnx: planning target volume of nasopharynx; PTVna: planning target volune of neck area; PTV: planning target volume 1.](jcav11p5210g002){#F2}

![Selected computed tomography slices to demonstrate the delineation of different risk target volumes. Red: PGTVnx; yellow: PGTVnd; green: PTVnx; pink: PTVna; blue: PTV1. Abbreviations: PGTVnx: planning target volume of nasopharyngeal GTV; PGTVnd: planning target volume of GTV in cervical lymph nodes; PTVnx: planning target volume of nasopharynx; PTVna: planning target volune of neck area; PTV: planning target volume 1.](jcav11p5210g003){#F3}

![Selected computed tomography slices to demonstrate the delineation of low-risk target volumes. Red: PGTVnx; yellow: PGTVnd; green: PTVnx; pink: PTVna; blue: PTV1. Abbreviations: PGTVnx: planning target volume of nasopharyngeal GTV; PGTVnd: planning target volume of GTV in cervical lymph nodes; PTVnx: planning target volume of nasopharynx; PTVna: planning target volume of neck area; PTV: planning target volume 1.](jcav11p5210g004){#F4}

![Target volumes and IMRT planning in a patient with stage T2N3M0 NPC. (**A**) MRI of the patient; (**B**) different risk target volumes and dose distributions; (**C**) DVH of IMRT. Abbreviations: IMRT: intensity-modulated radiotherapy; NPC: nasopharyngeal cancer; MRI, magnetic resonance imaging; DVH: dose-volume histogram.](jcav11p5210g005){#F5}

![Comparison of target volumes and dose distributions between two protocols. (**A**) target volumes and dose distributions of the China protocol; (**B**) target volumes and dose distributions of our protocol; (**C**) DVH of the China protocol; (**D**) DVH of our protocol. Abbreviation: DVH: dose-volume histogram.](jcav11p5210g006){#F6}

![Kaplan-Meier survival curves in 335 NPC patients. (**A**) LRRFS; (**B**) DMFS; (**C**) PFS; (**D**) OS. Abbreviations: NPC: nasopharyngeal cancer; LRRFS: locoregional relapse-free survival; DMFS: distant metastasis-free survival; PFS: progression-free survival; OS: overall survival.](jcav11p5210g007){#F7}

![Kaplan-Meier curves of LRRFS in 335 NPC patients with T- or N-stage. (A) T-stage; (B) N-stage. Abbreviations: LRRFS: locoregional relapse-free survival; NPC: nasopharyngeal cancer.](jcav11p5210g008){#F8}

###### 

Delineation of different risk target volumes using our protocol

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Target volume                                             Definition
  --------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------
  GTV in NP                                                 GTVnx

  GTV of LN                                                 GTVnd

  High-risk target volumes                                  PGTVnx = GTVnx + 0-3 mm + whole NP (5 mm submucosal)\
                                                            PGTVnd = GTVnd + 3 mm

  Intermediate-risk target volume for primary tumor         T1-2: CTVnx = GTVnx + 5-7 mm\
                                                            T3-4: CTVnx = GTVnx + 5-7 mm + whole NP (5 mm submucosal) + pterygoid + foramen lacerum\
                                                            PTVnx = CTVnx + 1-3 mm

  Nasal cavity-posterior part                               3 mm from the choana

  Maxillary sinuses-posterior part                          3 mm from the posterior wall

  Posterior ethmoid sinus                                   If invasion,

  Skull base                                                Cover foramina ovale, rotundum, and lacerum

  Cavernous sinus                                           Cover side involved only if T3-4

  Pterygoid fossae                                          \+

  Parapharyngeal spaces                                     Full coverage

  Sphenoid sinus                                            Inferior half if no invasion; whole if invasion

  Clivus                                                    Anterior third if no invasion; whole if invasion

  Intermediate-risk target volume for cervical lymph node   CTVna: cover bilateral level II plus VA if N0; cover bilateral level II, VA, plus at least one level ipsilateral below the involved levels\
                                                            PTVna = CTVna + 1-3 mm

  Bilateral RP, level II, III, IVa                          Bilateral level II plus VA if N0; bilateral level II, VA, plus at least one level ipsilateral below the involved levels

  Level IB                                                  IB LN+ve\
                                                            IIA LN+ve\
                                                            Invaded structure that drains to level IB as first echelon site

  Low-risk target volume                                    CTV: CTVnx + 3-7 mm for primary site; CTVna + 2-5 mm for cervical LN; cover lower neck and supraclavicular if N1-3 or omit if N0\
                                                            PTV = CTV + 1-3 mm
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

GTV: gross tumor volume; NP: nasopharynx; LN: lymph node; CTV: clinical target volume; PTV: planning target volume; GTVnx: GTV of nasopharynx; GTVnd: GTV of cervical lymph nodes; PGTVnx: planning target volume of nasopharyngeal GTV; PGTVnd: planning target volume of GTV in cervical lymph nodes; CTVnx: CTV of nasopharynx; PTVnx: planning target volume of CTV; CTVna: clinical target volume of neck area.

###### 

Baseline characteristics of the 335 newly diagnosed NPC patients enrolled in the study

  Characteristic           Number of patients   \%
  ------------------------ -------------------- ------
  **Age at diagnosis**                          
  Range (years)            17-79                
  Median age (years)       50                   
  **Sex**                                       
  Male                     240                  71.6
  Female                   95                   28.4
  **T stage^\*^**                               
  T1                       13                   3.9
  T2                       101                  30.1
  T3                       143                  42.7
  T4                       78                   23.3
  **N stage^\*^**                               
  N0                       4                    1.2
  N1                       64                   19.1
  N2                       235                  70.1
  N3                       32                   9.6
  **Clinical stage^\*^**                        
  II                       26                   7.8
  III                      208                  62.1
  IV                       101                  30.1
  **IC regimens**                               
  TPF                      54                   16.1
  TP                       155                  46.3
  GP                       71                   21.2
  PF                       22                   6.6
  No                       33                   9.8
  **Treatment modality**                        
  IC+CRT+AC                165                  49.3
  IC+IMRT+AC               14                   4.2
  IC+CRT                   115                  34.3
  IC+IMRT                  8                    2.4
  CRT                      13                   3.9
  CRT+AC                   20                   5.9

IC: induction chemotherapy; CRT: concurrent chemoradiotherapy; AC: adjuvant chemotherapy; IMRT: intensity-modulated radiotherapy; TPF: docetaxel/cisplatin/fluorouracil; TP: docetaxel/cisplatin; GP: gemcitabine/fluorouracil; FP: cisplatin/fluorouracil.

\*American Joint Committee on Cancer/International Union against Cancer staging system, seventh edition.

###### 

Profile of IC- and RT-related acute toxicities

  Adverse events        During IC (n)   During IMRT (n)                              
  --------------------- --------------- ----------------- ---- ---- ----- ----- ---- ---
                        1               2                 3    4    1     2     3    4
  **Hematologic**                                                                    
  Leukopenia            35              92                58   36   76    53    32   3
  Neutropenia           41              62                57   52   68    47    29   5
  Anemia                93              29                11   1    42    17    5    0
  Thrombocytopenia      55              18                8    5    33    13    5    2
  Liver function        36              15                6    0    10    5     0    0
  Renal function        9               2                 1    0    0     0     0    0
  **Non-hematologic**                                                                
  Mucositis             25              16                6    1    181   123   23   0
  Dermatitis            37              5                 0    0    261   57    11   0
  Diarrhea              31              19                7    0    13    2     0    0
  Nausea/vomiting       82              58                23   2    35    22    13   0

IC: induction chemotherapy; RT: radiotherapy; IMRT: intensity-modulated radiotherapy.

###### 

Comparison of biological equivalent doses among three protocols

  Variable   Present protocol   China protocol   0615/0225 protocol                          
  ---------- ------------------ ---------------- -------------------- -------- ------------- --------
  α/β        Dose               BED              Dose                 BED      Dose          BED
  3          70.5 Gy/30F        125.73           70.4 Gy/32F          122.03   70 Gy/33F     119.40
  10         88.13              85.89            84.79                                       
  3          63 Gy/30F          107.1            64 Gy/32F            106.67   62.7 Gy/33F   102.41
  10         76.23              85.89            74.61                                       
  3          60 Gy/30F          100              60.8 Gy/32F          99.31    59.4 Gy/33F   95.04
  10         72                 72.35            70.1                                        
  3          51 Gy/30F          79.9             54.4 Gy/32F          85.23    50.4 Gy/33F   80.64
  10         59.67              63.65            59.47                                       

[^1]: \*These authors have contributed equally to this work.

[^2]: Competing Interests: The authors have declared that no competing interest exists.
